- Home
- CERO vs KZIA Comparison
CERO vs KZIA Comparison
Compare CERO & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- KZIA
- Stock Information
- Founded
- CERO 2017
- KZIA 1994
- Country
- CERO United States
- KZIA Australia
- Employees
- CERO N/A
- KZIA N/A
- Industry
- CERO
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- CERO
- KZIA Health Care
- Exchange
- CERO Nasdaq
- KZIA Nasdaq
- Market Cap
- CERO 8.4M
- KZIA 7.8M
- IPO Year
- CERO N/A
- KZIA 1999
- Fundamental
- Price
- CERO $2.34
- KZIA $1.42
- Analyst Decision
- CERO
- KZIA Strong Buy
- Analyst Count
- CERO 0
- KZIA 1
- Target Price
- CERO N/A
- KZIA $20.00
- AVG Volume (30 Days)
- CERO 80.5M
- KZIA 116.4K
- Earning Date
- CERO 02-20-2025
- KZIA 11-15-2024
- Dividend Yield
- CERO N/A
- KZIA N/A
- EPS Growth
- CERO N/A
- KZIA N/A
- EPS
- CERO N/A
- KZIA N/A
- Revenue
- CERO N/A
- KZIA $1,655,324.00
- Revenue This Year
- CERO N/A
- KZIA $806.89
- Revenue Next Year
- CERO N/A
- KZIA N/A
- P/E Ratio
- CERO N/A
- KZIA N/A
- Revenue Growth
- CERO N/A
- KZIA 248000.00
- 52 Week Low
- CERO $2.22
- KZIA $1.39
- 52 Week High
- CERO $1,280.00
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- CERO 32.54
- KZIA 20.74
- Support Level
- CERO $2.83
- KZIA $1.42
- Resistance Level
- CERO $3.50
- KZIA $1.89
- Average True Range (ATR)
- CERO 1.13
- KZIA 0.24
- MACD
- CERO 0.05
- KZIA 0.02
- Stochastic Oscillator
- CERO 1.43
- KZIA 1.40
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.